Sugi Predict

Sugi Predict / Compounds / SCHEMBL497031

SCHEMBL497031

SCHEMBL497031

N#CN=C1NC(=O)C(=Cc2ccc3c(c2)OCO3)S1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.67
▸ DYRK1B Q9Y463 6/20 0.67
▸ CSNK2A2 P19784 5/20 0.67
▸ CSNK2B P67870 5/20 0.67
▸ CSNK2A1 P68400 5/20 0.67
▸ CSNK2A3 Q8NEV1 5/20 0.67
▸ CDC25B P30305 2/20 0.67
▸ MAPK9 P45984 1/20 0.62
▸ GSK3B P49841 1/20 0.56
▸ PTGS2 P35354 1/20 0.54
▸ KMT2A Q03164 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ DYRK3 O43781 5/20 0.49
▸ DYRK2 Q92630 5/20 0.49
▸ PIM1 P11309 4/20 0.49
▸ HPGD P15428 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ CDK5 Q00535 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497030 1.00 DYRK1A (0.67) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL5758972 0.84 HPGD (0.75) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL5758745 0.84 HPGD (0.75) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL496829 0.81 DYRK1A (0.67) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL497247 0.81 DYRK1A (0.67) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL496943 0.81 DYRK1A (0.67) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL497249 0.81 DYRK1A (0.67) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL2882197 0.81 GSK3B (0.83) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL1249098 0.81 GSK3B (0.83) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1
SCHEMBL29369746 0.81 GSK3B (0.83) DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US claimed
US-20070021447-A1 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-01-25 — — US claimed
JP-2007500171-A — — 2007-01-11 — — JP claimed
EP-1648452-A1 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2006-04-26 — — EP claimed
WO-2005011686-A1 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-02-10 — — WO claimed
US-8106214-B2 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors MERCK SERONO SA (CH) 2012-01-31 — — US disclosed
EP-1648452-B1 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS MERCK SERONO SA (CH) 2009-07-22 — — EP disclosed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 — — US disclosed
EP-1931424-A2 P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2008-06-18 — — EP disclosed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 — — EP disclosed
WO-2007030360-A2 P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2007-03-15 — — WO disclosed
US-20070021447-A1 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-01-25 — — US disclosed
EP-1648452-A1 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2006-04-26 — — EP disclosed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 — — WO disclosed
WO-2005011686-A1 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-02-10 — — WO disclosed
US-5750712-A DIABETIC THERAPY FUJIMOTO BROTHERS CO., LTD. (JP) 1998-05-12 — — US disclosed
EP-0697410-A1 54-substituted alkylidene 2-(N-cyanoimino)-thiazolidin-4-one derivatives, their preparation and their use as aldose reductase inhibitors Fujimoto Pharmaceutical Co, Ltd (JP) 1996-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 DYRK1A 362/4885DYRK1B 389/4885CSNK2A2 388/4885
US-20070021447-A1 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors PI4K2B, PI4KA, PTK2B DYRK1A 2093/4885DYRK1B 1813/4885CSNK2A2 1038/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 DYRK1A 1259/4885DYRK1B 1267/4885CSNK2A2 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.